Baird Financial Group’s OncoMed Pharmaceuticals, Inc. OMED Stock Holding History

Baird Financial Group’s Portfolio OMED Stock Details OMED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-12,000	Closed	-$12K	–	1577
2019 Q1	$12K	Hold	12,000	–	–	﹤0.01%	1282
2018 Q4	$9K	Hold	12,000	–	–	﹤0.01%	1263
2018 Q3	$25K	Hold	12,000	–	–	﹤0.01%	1323
2018 Q2	$28K	Hold	12,000	–	–	﹤0.01%	1275
2018 Q1	$38K	Hold	12,000	–	–	﹤0.01%	1242
2017 Q4	$49K	Hold	12,000	–	–	﹤0.01%	1253
2017 Q3	$54K	Hold	12,000	–	–	﹤0.01%	1224
2017 Q2	$40K	Hold	12,000	–	–	﹤0.01%	1218
2017 Q1	$111K	Hold	12,000	–	–	﹤0.01%	1197
2016 Q4	$93K	Buy	+12,000	New	+$110K	﹤0.01%	1175

Baird Financial Group's OMED Position: Q2 2019 in Review

Baird Financial Group sold out of OncoMed Pharmaceuticals, Inc. (OMED) in Q2 2019, closing a stake of 12,000 shares — an estimated $12K sold.

Baird Financial Group first reported a position in OMED in Q4 2016 and held it in 10 quarters. The position peaked at $111K in Q1 2017. 0 funds tracked by Wall St. Rank hold OMED as of Q2 2019.

Baird Financial Group reported no remaining OncoMed Pharmaceuticals, Inc. position as of Q2 2019 after selling out during the quarter.
Baird Financial Group sold 12,000 OncoMed Pharmaceuticals, Inc. shares in Q2 2019, an estimated $12K.
Baird Financial Group first reported a position in OncoMed Pharmaceuticals, Inc. in Q4 2016 and held it in 10 quarters.
Baird Financial Group's OncoMed Pharmaceuticals, Inc. position peaked at $111K in Q1 2017.
0 funds tracked by Wall St. Rank held OncoMed Pharmaceuticals, Inc. as of Q2 2019.

Based on Baird Financial Group's 13F filing for Q2 2019, filed 14 Aug 2019.